HC-022 / HC Biopharma - LARVOL DELTA

The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: HC Biopharma Inc.

New P1 trial • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

HC022-I-001: Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects. (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: HC Biopharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus